Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Astra Zeneca, Bristol-Myers Squibb
Age
35–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with type 2 diabetes and inadequate glycemic control, defined as A1C ≥ 7.0 and ≤ 10.0% at the enrollment visit
Subjects should have been receiving either metformin therapy OR metformin therapy AND one insulin secretagogue for at least 12 weeks prior to enrollment
C-peptide ≥ 1.0 ng/ml (0.34 nmol/l)
BMI ≤ 45.0 kg/m2
You may not be if
Urine albumin to creatinine ratio (UACR) \> 1,800 mg/g (203.4 mg/mmol/Cr)
Aspartate Aminotransferase (AST) \> 3X Upper limit of normal (ULN)
Alanine aminotransferase (ALT) \> 3X ULN
Serum Total Bilirubin \> 2 mg/dL (34.2 μmol/l)
Serum Creatinine (Scr) ≥ 1.50 mg/dL (133 μmol/l) for men; SCr ≥ 1.40 mg/dL (124 μmol/l) for women
Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases
Clareo Health | Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
